The Zhitong Finance App learned that recently, NewAmsterdam Pharma (NAMS.US) announced the results of its Phase 2 trial to develop the CETP inhibitor Obicetrapib during the 2024 American College of Cardiology (ACC). Analysis showed that obicetrapib, as a single drug or in combination with ezetimibe, can effectively reduce low density lipoprotein cholesterol (LDL-C) levels in patients with dyslipidemia (dyslipidemia). NewAmsterdam also announced that its associated Phase 3 key trial, Prevail, has reached the goal of recruiting 9,000 patients with a history of atherosclerotic cardiovascular disease (ASCVD).
According to information, the ROSE2 clinical phase 2 trial announced this time aims to evaluate the efficacy and safety of obicetrapib alone or in combination with ezetimibe as adjuvant therapy for patients with dyslipidemia receiving high-intensity statins compared to placebo. Patients with LDL-C levels greater than 70 mg/dL at the time of enrolment were treated for 12 weeks in the trial.
The analysis showed that obicetrapib alone or in combination with ezetimibe significantly (all indicators P<0.05) reduced LDL-C (43.5% and 63.4%), non-high-density lipoprotein cholesterol (non-HDL-C, 37.5% and 55.6%), apoB (24.2% and 34.4%), total LDL-P (54.8% and 72.1%), small LDL-P (92.7% and 95.4%), small LDL-P (92.7% and 95.4%), and small low-density lipoprotein cholesterol (SDLDL) C, 30.9% and 44.4%) levels, and raised high-density lipoprotein cholesterol levels (HDL-C, 142% and 136%).